Partial-onset Seizures
📧 Sign up to get email alerts when something new happens for Partial-onset Seizures.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2017-10-11FDA Approved: LYRICA CR — Original Application (Viatris Specialty LLC)
FDA approves LYRICA CR (pregabalin) under an Original Application for an extended-release formulation of pregabalin.
-
FDA approval · 2017-09-28FDA Approved: LEVETIRACETAM — Original Application (Hisun Pharmaceuticals USA, Inc.)
FDA approved Hisun Pharmaceuticals USA, Inc.'s original application for a generic levetiracetam product.
-
FDA approval · 2017-09-14FDA Approved: BRIVIACT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for Briviact (brivaracetam) submitted by UCB, Inc.
-
FDA approval · 2017-09-14FDA Approved: BRIVIACT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for Briviact (brivaracetam) from UCB, authorizing changes to its labeling.
-
FDA approval · 2017-09-13FDA Approved: APTIOM — Supplemental Application (Sumitomo Pharma America, Inc.)
The FDA approved a supplemental application for APTIOM (eslicarbazepine acetate) submitted by Sumitomo Pharma America, Inc.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2017-08-14FDA Approved: LEVETIRACETAM — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application to authorize Aurobindo Pharma Limited to manufacture levetiracetam (generic) in the United States.
-
FDA approval · 2017-07-26FDA Approved: FYCOMPA — Supplemental Application (Eisai Inc.)
FDA approved Eisai Inc.'s supplemental application for FYCOMPA (perampanel), updating the labeling to reflect the approved change.
-
FDA approval · 2017-06-09FDA Approved: LEVETIRACETAM — Supplemental Application (Prasco Laboratories)
FDA approves a supplemental application for levetiracetam by Prasco Laboratories, enabling a generic version to be marketed.
-
FDA approval · 2017-04-24FDA Approved: KEPPRA XR — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for KEPPRA XR (levetiracetam), authorizing the extended-release formulation from UCB, for use in epi…
-
FDA approval · 2017-03-07FDA Approved: APTIOM — Supplemental Application (Sumitomo Pharma America, Inc.)
The FDA approved a supplemental application for APTIOM (eslicarbazepine acetate) submitted by Sumitomo Pharma America, Inc.
-
FDA approval · 2016-12-22FDA Approved: LYRICA — Supplemental Application (Parke-Davis Div of Pfizer Inc)
The FDA approved a supplemental application for LYRICA (pregabalin) submitted by Parke-Davis Division of Pfizer Inc.
-
FDA approval · 2016-11-02FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for VIMPAT (lacosamide) from UCB, Inc., resulting in an update to its labeling for epilepsy-related …
-
FDA approval · 2016-09-16FDA Approved: LEVETIRACETAM — Original Application (Mylan Institutional LLC)
FDA approved an original ANDA for levetiracetam from Mylan Institutional LLC, enabling a generic version of the anticonvulsant to reach the …
-
FDA approval · 2016-08-01FDA Approved: LEVETIRACETAM SOLUTION — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for LEVETIRACETAM SOLUTION (levetiracetam) from Chartwell RX, LLC, approving a new solution formulat…
-
FDA approval · 2016-07-18FDA Approved: ZONISAMIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approves a supplemental application for zonisamide submitted by Sun Pharmaceutical Industries, Inc.
-
FDA approval · 2016-06-21FDA Approved: SABRIL — Supplemental Application (Lundbeck Pharmaceuticals LLC)
FDA approved a supplemental application for Sabril (vigabatrin) from Lundbeck Pharmaceuticals LLC.
-
FDA approval · 2016-04-29FDA Approved: FYCOMPA — Original Application (Eisai Inc.)
The FDA granted original approval for FYCOMPA (perampanel) from Eisai Inc. for add-on therapy in patients with partial-onset seizures, marki…
-
FDA approval · 2016-02-26FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for VIMPAT (lacosamide) from UCB, Inc., expanding/adjusting its approved labeling for the drug.
-
FDA approval · 2016-02-18FDA Approved: BRIVIACT — Original Application (UCB, Inc.)
FDA approved Briviact (brivaracetam) based on UCB, Inc.'s original NDA, establishing it as an adjunctive therapy for partial-onset seizures …
-
FDA approval · 2016-02-18FDA Approved: BRIVIACT — Original Application (UCB, Inc.)
The FDA approved Briviact (brivaracetam) as an adjunctive treatment for partial-onset seizures in adults and in children aged 4 years and ol…
-
FDA approval · 2016-02-18FDA Approved: BRIVIACT — Original Application (UCB, Inc.)
FDA approved Briviact (brivaracetam) under its original application by UCB, Inc. for adjunctive treatment of partial-onset seizures in epile…
-
FDA approval · 2016-02-01FDA Approved: LEVETIRACETAM — Original Application (Eugia US LLC)
The FDA approved an Abbreviated New Drug Application (ANDA) for levetiracetam from Eugia US LLC, authorizing the marketing of a generic vers…
-
FDA approval · 2016-01-06FDA Approved: APTIOM — Supplemental Application (Sumitomo Pharma America, Inc.)
The FDA approved a supplemental application for APTIOM (eslicarbazepine acetate) submitted by Sumitomo Pharma America, Inc. The approval per…
-
FDA approval · 2015-12-14FDA Approved: FYCOMPA — Supplemental Application (Eisai Inc.)
FDA approved Eisai's supplemental application for FYCOMPA (perampanel) to update the labeling and potentially expand its approved uses for e…
-
FDA approval · 2015-12-14FDA Approved: LEVETIRACETAM — Supplemental Application (Prasco Laboratories)
The FDA approved a supplemental application for Levetiracetam from Prasco Laboratories, resulting in updated labeling for this antiepileptic…